Genentech

The FDA approved tocilizumab-anoh (Avtozma) IV formulation on August 6, 2025, for treating cytokine release syndrome in patients aged 2 years and older.

Roche's cobas Respiratory 4-flex becomes the first FDA-cleared assay utilizing innovative TAGS technology, simultaneously detecting SARS-CoV-2, influenza A, influenza B, and RSV in a single test.

The Global Alzheimer's Platform Foundation and Genentech announced a collaboration to expand access to Alzheimer's clinical trials for underrepresented communities, including racial and ethnic minorities, women, and economically disadvantaged individuals.

Roche's pivotal Phase IIb ALIENTO study met its primary endpoint, showing astegolimab reduced annualized exacerbation rate by 15.4% in COPD patients at 52 weeks.

Ryan Richardson will step down as Chief Strategy Officer from BioNTech's Management Board on September 30, 2025, after serving since January 2020.

The World Health Organization has included ziresovir (10mg) from Shanghai Ark Biopharmaceutical in its PADO-RSV priority list, making it the first and only RSV antiviral drug selected for the program.

Xaira Therapeutics has appointed biotech veteran Jeff Jonker as President and Chief Operating Officer to help scale its AI-enabled drug discovery platform and drive the next phase of growth.

The FDA has approved Omlyclo (omalizumab-igec) as the first biosimilar interchangeable with Xolair for treating allergic asthma, chronic rhinosinusitis with nasal polyps, chronic urticaria, and food allergies.

Scientists at The Herbert Wertheim UF Scripps Institute developed a novel antibody-drug conjugate combining tiancimycin, a natural compound from soil microbes, with a "double-decker" antibody targeting CD79b for diffuse large B cell lymphoma treatment.

The pharmaceutical industry is experiencing one of the biggest patent cliffs since 2010, with blockbuster drugs including Merck's Keytruda, BMS's Eliquis, and Johnson & Johnson's Darzalex losing market exclusivity between 2025-2030.